Inherited disorders of calcium and phosphate metabolism

Current Opinion in Pediatrics

Volumn 26, Issue 2, 2014, Pages 215-222

  Gattineni, Jyothsna ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Fibroblast growth factor 23; Hyperparathyroidism; Hypoparathyroidism; Klotho

Indexed keywords

CALCIUM HOMEOSTASIS; CHONDRODYSPLASIA; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FIBROBLAST GROWTH FACTOR 23 DEFICIENCY DISORDER; FIBROBLAST GROWTH FACTOR 23 EXCESS SYNDROME; FIBROBLAST GROWTH FACTOR 23 INDEPENDENT HYPOPHOSPHATEMIC DISORDER; FIBROBLAST GROWTH FACTOR INDEPENDENT HYPERPHOSPHATEMIC DISORDER; GENETIC DISORDER; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; IDIOPATHIC HYPERCALCEMIA OF INFANCY; JANSEN METAPHYSEAL CHONDRODYSPLASIA; NEONATAL SEVERE PRIMARY HYPERPARATHYROIDISM; PHOSPHATE METABOLISM; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PSEUDOHYPOPARATHYROIDISM; REVIEW; RICKETS; VITAMIN D DEPENDENT RICKETS; COMPLICATION; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GENETIC COUNSELING; GENETICS; HOMEOSTASIS; INFANT; METABOLIC BONE DISEASE; METABOLISM; NEWBORN; PRESCHOOL CHILD; VITAMIN D DEFICIENCY;

BETA GLUCURONIDASE; CALCIUM; CALCIUM SENSING RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE;

BONE DISEASES, METABOLIC; CALCIUM; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; EARLY DIAGNOSIS; FIBROBLAST GROWTH FACTORS; GENETIC COUNSELING; GLUCURONIDASE; HOMEOSTASIS; HUMANS; INFANT; INFANT, NEWBORN; PHOSPHATES; RECEPTORS, CALCIUM-SENSING; VITAMIN D DEFICIENCY;

EID: 84897028917     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000064     Document Type: Review

References (63)

1. Matkovic V, Heaney RP. Calcium balance during human growth: Evidence for threshold behavior. Am J Clin Nutr 1992; 55:992-996.
2. Bronner F, Pansu D, Stein WD. An analysis of intestinal calcium transport across the rat intestine. Am J Physiol 1986; 250:G561-G569.
3. Bronner F. Mechanisms of intestinal calcium absorption. J Cell Biochem 2003; 88:387-393.
4. Moore EW. Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J Clin Invest 1970; 49:318-334.
5. Friedman PA, Gesek FA. Cellular calcium transport in renal epithelia: Measurement, mechanisms, and regulation. Physiol Rev 1995; 75:429-471.
6. Friedman PA. Calcium transport in the kidney. Curr Opin Nephrol Hypertens 1999; 8:589-595.
7. Sutton RA, Dirks JH. The renal excretion of calcium: A review of micropuncture data. Can J Physiol Pharmacol 1975; 53:979-988.
8. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev 2005; 85:373-422.
9. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2-sensing receptor from bovine parathyroid. Nature 1993; 366:575-580.
10. Silva BC, Costa AG, Cusano NE, et al. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest 2011; 34:801-810.
11. Hoenderop JG, Dardenne O, Van AM, et al. Modulation of renal Ca2 transport protein genes by dietary Ca2 and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002; 16:1398-1406.
12. Van AM, Hoenderop JG, Van Der Kemp AW, et al. Regulation of the epithelial Ca2 channels in small intestine as studied by quantitative mRNA detection. Am J Physiol Gastrointest Liver Physiol 2003; 285:G78-G85.
13. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc Natl Acad Sci U S A 2001; 98:13324-13329.
14. Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol 2012; 27:1477-1487.
15. Hoorn EJ, Zietse R. Disorders of calcium and magnesium balance: A physiology-based approach. Pediatr Nephrol 2013; 28:1195-1206.
16. Novelli A, Sabani M, Caiola A, et al. Diagnosis of DiGeorge and Williams syndromes using FISH analysis of peripheral blood smears. Mol Cell Probes 1999; 13:303-307.
17. Ryan AK, Goodship JA, Wilson DI, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: A European collaborative study. J Med Genet 1997; 34:798-804.
18. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996; 335:1115-1122.
19. Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2)-sensing receptor gene mutation. Nat Genet 1994; 8:303-307.
20. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes 2012; 19:443-451.
21. Al-Azem H, Khan AA. Hypoparathyroidism. Best Pract Res Clin Endocrinol Metab 2012; 26:517-522.
22. Davies SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. J Med Genet 1993; 30:101-103.
23. Yu S, Yu D, Lee E, et al. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A 1998; 95:8715-8720.
24. Bastepe M, Lane AH, Juppner H. Paternal uniparental isodisomy of chromosome 20q-And the resulting changes in GNAS1 methylation-As a plausible cause of pseudohypoparathyroidism. Am J Hum Genet 2001; 68:1283-1289.
25. de Nanclares GP, Fernandez-Rebollo E, Santin I, et al. Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab 2007; 92:2370-2373.
26. Fraser D, Kooh SW, Kind HP, et al. Pathogenesis of hereditary vitamin-Ddependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973; 289:817-822.
27. Fu GK, Lin D, Zhang MY, et al. Cloning of human 25-hydroxyvitamin D-1 alphahydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol 1997; 11:1961-1970.
28. Brooks MH, Bell NH, Love L, et al. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978; 298:996-999.
29. Liberman UA, Samuel R, Halabe A, et al. End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet 1980; 1:504-506.
30. Davies JH, Shaw NJ. Investigation and management of hypercalcaemia in children. Arch Dis Child 2012; 97:533-538.
31. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62:377-411.
32. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000; 343:1863-1875.
33. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 2008; 22:129-148.
34. Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. Curr Opin Pediatr 2010; 22:508-515.
35. Castanet M, Mallet E, Kottler ML. Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations. J Pediatr 2013; 163:1208-1210.
36. Lightwood R, Stapleton T. Idiopathic hypercalcaemia in infants. Lancet 1953; 265:255-256.
37. Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011; 365:410-421.
38. Schipani E, Kruse K, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-Type metaphyseal chondrodysplasia. Science 1995; 268:98-100.
39. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61:91-104.
40. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297:F282-F291.
41. Hu MC, Shi M, Zhang J, et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24:3438-3450.
42. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/ osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82:674-681.
43. Hypophosphatemic rickets, X-linked dominant; XLHR. OMIM. 2011.
44. Carpenter TO, Imel EA, Holm IA, et al. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26:1381-1388.
45. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012; 30:1-9.
46. Alon US, Levy-Olomucki R, Moore WV, et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 2008; 3:658-664.
47. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009; 24:1879-1888.
48. Aono Y, Hasegawa H, Yamazaki Y, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res 2011; 26:803-810.
49. Levy-Litan V, Hershkovitz E, Avizov L, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010; 86:273-278.
50. Lorenz-Depiereux B, Bastepe M, et-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248-1250.
51. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315.
52. Imel EA, Econs MJ. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr Endocrinol Rev 2007; 4 (Suppl 4):434-439.
53. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688-1695.
54. Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008; 105:3455-3460.
55. Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179-192.
56. Lorenz-Depiereux B, et-Pages A, Eckstein G, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78:193-201.
57. Magen D, Berger L, Coady MJ, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 2010; 362:1102-1109.
58. Shiber JR, Mattu A. Serum phosphate abnormalities in the emergency department. J Emerg Med 2002; 23:395-400.
59. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16:3389-3396.
60. Neven E, D'Haese PC. Vascular calcification in chronic renal failure: What have we learned from animal studies? Circ Res 2011; 108:249-264.
61. et-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390.
62. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581.
63. Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117:2684-2691.